Brief: Oragenics Reports Favorable Toxicology Results For Its COVID-19 Intranasal Vaccine Candidate
22/12/2022 12:34
Dec 22 (Reuters) - Oragenics Inc OGEN.A :
* ORAGENICS REPORTS FAVORABLE TOXICOLOGY RESULTS FOR ITS
COVID-19
INTRANASAL VACCINE CANDIDATE
* NO TOXICITY FOUND IN NT-COV2-1, SUPPORTS REGULATORY FILING
FOR
PHASE 1 STUDY
Source text for Eikon: ID:nBwbgqqc7a
Further company coverage: OGEN.A
((Reuters.Briefs@thomsonreuters.com))
Recent news on Oragenics
See all newsBrief: Oragenics Reports Continued Clinical Progress, Provides Regulatory And NYSE American Listing Update
Brief: Oragenics Signs Letter Of Intent To License Cardiodialysis™ Technology From Sigyn Therapeutics To Target Tbi-Induced Systemic Inflammation
Brief: Oragenics Inc - Signs Letter Of Intent To License Cardiodialysis From Sigyn Therapeutics - SEC Filing
Brief: Oragenics Activates Second Site In Phase Iia Clinical Trial Of Onp-002 For Concussion And Mild Traumatic Brain Injury.
Brief: Oragenics Enters Settlement Agreement With Ladenburg Thalmann - Sec Filing